Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRAX-944 Phase 2 Part B in adults with essential tremor
ACTRN12622000408785Phase 2Recruiting
- Sponsor
- Praxis Precision Medicines
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in essential tremor (ET) comparing Open-label titration then randomized to PRAX-944 with Open-label titration then randomized to placebo (2 arms). Primary endpoint: Incidence and severity of adverse events. Started Aug 2021; status: recruiting.
02
Drugs
ulixacaltamide
03
Conditions
essential tremor (ET)
Beyond the preview
Go deeper on ACTRN12622000408785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622000408785.